A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

Please provide your email address to receive an email when new articles are posted on . Use of GLP-1 receptor agonists in diabetes was associated with reduced risk for RA and gout. No reduction in PsA ...

Researchers create the first sex-specific GLP-1 brain atlas, revealing why weight-loss drugs work differently in men and women.

Patients with lupus and type 2 diabetes are predisposed to a disproportionate risk of atherosclerotic cardiovascular disease and chronic kidney disease. A study of this patient population showed that ...

GLP-1 is an incretin hormone that is primarily secreted by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion, including carbohydrates, fats, and ...

In older adults with type 2 diabetes (T2D), the initiation of GLP-1 receptor agonists vs drugs such as DPP-4 and SGLT2 inhibitors was associated with an 11% increased risk for fragility fractures.

In January 2025, we reported about an observational study of nearly 2 million U.S. military veterans that showed a broad spectrum of possible risks and benefits associated with GLP-1 receptor agonists ...